Socioeconomic Implications of Long-Term Warfarin Use
Tóm tắt
Current guidelines recommend the use of warfarin in all patients with atrial fibrillation (AF) and/or an artificial heart valve who are at high risk of thromboembolism. While anticoagulation with warfarin greatly reduces this risk, a careful system of monitoring and management is necessary to maintain a therapeutic dose and minimize adverse events. This rigorous process places a burden on providers, and many patients managed in typical office practices are not optimally anticoagulated. To improve the quality and efficiency of anticoagulation and remove its burden from office-based physicians, newer treatment models have evolved, including anticoagulation clinics and self-monitoring by patients at home. While these newer models often incorporate innovative programs to streamline warfarin management, little is known about their individual or relative economic merits or those of traditional office-based care. The routine costs of anticoagulation within any model have not been well documented. The cost of warfarin is readily available; however, attendant expenses, such as dose adjustment, laboratory testing, and medical encounters, are difficult to gauge. Because of these challenges in collecting practice data, most estimates of the cost of anticoagulation services have relied upon assumptions about practice patterns. Assessing the cost of anticoagulation is easier in a clinic setting because all costs relate exclusively to anticoagulation. A recent study of anticoagulation clinics estimated that annual direct costs per patient for anticoagulation services totaled approximately $US280–$US380 (2002 values). Bleeding and other complications experienced by anticoagulated patients add additional types of costs, with inpatient care accounting for more than one-half of the total cost of managing excessive anticoagulation. When quality of life is considered alongside costs to gauge the cost effectiveness of warfarin therapy versus aspirin (acetylsalicylic acid), warfarin appears to be cost-saving in patients at high stroke risk and cost effective in those at moderate risk. For patients at lower risk of stroke, aspirin is more cost effective than warfarin. With the aging of the population and consequent increases in patient groups requiring anticoagulation, the US healthcare system greatly needs improvements to anticoagulation management. New research must determine which models of management will provide the most favorable outcomes for high-risk patients at the lowest cost to payors and society.
Tài liệu tham khảo
American Heart Association. Heart Disease and Stroke Statistics: 2003 Update. Dallas (TX): American Heart Association, 2002
Feinberg WM, Blackshear JL, Laupacis A, et al. Prevalence, age distribution, and gender of patients with atrial fibrillation; analysis and implications. Arch Intern Med 1995; 155(5): 469–73
Hirsh J, Dalen J, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001 Jan; 119 Suppl. 1: 8S–21S
Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation): developed in Collaboration with the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol 2001 Oct; 38(4): 1231–65
Bonow RO, Carabello B, de Leon AC Jr, et al. ACC/AHA guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association. Task Force on Practice Guidelines. (Committee on Management of Patients with Valvular Heart Disease? J Am Coll Cardiol 1998; 32(5): 1486–588
Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996; 348 (9025): 423–8
Cannegieter SC, Rosendaal FR, Wintzen AR, et al. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995; 333(1): 11–7
Hart RG, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999; 131(7): 492–501
Stein PD, Alpert JS, Bussey HI, et al. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 2001 Jan; 119 Suppl. 1: 220S–7S
Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991 Aug; 22(8): 983–8
Atrial fibrillation investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449–57
Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation 1994 Feb; 89(2): 635–41
Hafner JW, Belknap SM, Squillante MD, et al. Adverse drug events in emergency department patients. Ann Emerg Med 2002 Mar; 39(3): 258–67
Ansell J, Hirsh J, Dalen J, et al. Managing oral anticoagulant therapy. Chest 2001 Jan; 119 Suppl. 1: 22S–38S
Fihn SD, McDonell M, Martin D, et al. Risk factors for complications of chronic anticoagulation: a multicenter study. Warfarin Optimized Outpatient Follow-up Study Group. Ann Intern Med 1993 Apr; 118(7): 511–20
Gullov AL, Koefoed BG, Petersen P. Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation: the AFASAK 2 study. Atrial fibrillation aspirin and anticoagulation. Arch Intern Med 1999 Jun; 159(12): 1322–8
Petersen P, Godtfredsen J, Boysen G. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: The Copenhagen AFASAK study. Lancet 1989; I: 175–9
EAFT (European Atrial Fibrillation Trial) study group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342(8882): 1255–62
Brass LM, Krumholz HM, Scinto JM, et al. Warfarin use among patients with atrial fibrillation. Stroke 1997 Dec; 28(12): 2382–9
Brass LM, Krumholz HM, Scinto JD, et al. Warfarin use following ischemic stroke among Medicare patients with atrial fibrillation. Arch Intern Med 1998 Oct; 158(19): 2093–100
Go AS, Hylek EM, Borowsky LH. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Ann Intern Med 1999; 131(12): 927–34
Munschauer FE, Priore RL, Hens M, et al. Thromboembolism prophylaxis in chronic atrial fibrillation: practice patterns in community and tertiary-care hospitals. Stroke 1997; 28(1): 72–6
Whittle J, Wickenheiser L, Venditti L. Is warfarin underused in the treatment of elderly persons with atrial fibillation? Arch Intern Med 1997; 157(4): 441–5
Hylek EM, Chang YC, Skates SJ, et al. Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation. Arch Intern Med 2000 Jun; 160(11): 1612–7
Fihn SD, Callahan CM, Martin DC, et al. The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics. Ann Intern Med 1996 Jun; 124(11): 970–9
White RH, McKittrick T, Takakuwa J, et al. Management and prognosis of life-threatening bleeding during warfarin therapy. National Consortium of Anticoagulation Clinics. Arch Intern Med 1996; 156(11): 1197–201
Gurwitz JH, Avorn J, Ross-Degnan D, et al. Aging and the anticoagulant response to warfarin therapy. Ann Intern Med 1992 Jun; 116(11): 901–4
Buckingham TA, Hatala R. Anticoagulants for atrial fibrillation: why is the treatment rate so low?. Clin Cardiol 2002 Oct; 25(10): 447–54
Albers GW, Yim JM, Belew KM. Status of antithrombotic therapy for patients with atrial fibrillation in university hospitals. Arch Intern Med 1996; 156(20): 2311–6
Gage BF, Boechler M, Doggette AL, et al. Adverse outcomes and predictors of underuse of antithrombotic therapy in medicare beneficiaries with chronic atrial fibrillation. Stroke 2000 Apr; 31(4): 822–7
Antani MR, Byeth RJ, Covinsky KE. Failure to prescribe warfarin to patients with nonrheumatic atrial fibrillation. J Gen Intern Med 1996; 11(12): 713–20
Samsa GP, Matchar DB, Goldstein LB, et al. Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities. Arch Intern Med 2000 Apr; 160(7): 967–73
Johnston JA, Cluxton RJ, Heaton PC, et al. Predictors of warfarin use among Ohio Medicaid patients with new-onset nonvalvular atrial fibrillation. Arch Intern Med 2003; 163: 1705–10
McCrory DC, Matchar DB, Samsa G, et al. Physician attitudes about anticoagulation for nonvalvular atrial fibrillation in the elderly. Arch Intern Med 1995 Feb; 155(3): 277–81
Monette J, Gurwitz JH, Rochon PA, et al. Physician attitudes concerning warfarin for stroke prevention in atrial fibrillation: results of a survey of long-term care practitioners. J Am Geriatr Soc 1997 Sep; 45(9): 1060–5
Stafford RS, Singer DE. Recent national patterns of warfarin use in atrial fibrillation. Circulation 1998; 97(13): 1231–3
Gross CP, Vogel EW, Dhond AJ, et al. Factors influencing physicians’ reported use of anticoagulation therapy in nonvalvular atrial fibrillation: a cross-sectional survey. Clin Ther 2003; 25(6): 1750–64
Kutner M, Nixon G, Silverstone F. Physicians’ attitudes toward oral anticoagulants and antiplatelet agents for stroke prevention in elderly patients with atrial fibrillation. Arch Intern Med 1991 Oct; 151(10): 1950–3
Rodgers H, Sudlow M, Dobson R, et al. Warfarin anticoagulation in primary care: a regional survey of present practice and clinicians’ views. Br J Gen Pract 1997 May; 47(418): 309–10
Bungard TJ, Ghali WA, Teo KK, et al. Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med 2000 Jan; 160(1): 41–6
Barcellona D, Contu P, Marongiu F. Patient education and oral anticoagulant therapy. Haematologica 2002 Oct; 87(10): 1081–6
Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med 1998 Aug; 158(15): 1641–7
Matchar DB, Samsa GP, Cohen SJ, et al. Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: results of the managing anticoagulation services trial. Am J Med 2002 Jul; 113(1): 42–51
Caffee AE, Teichman PG. Improving anticoagulation management at the point of care. Fam Pract Manag 2002 Feb; 9(2): 35–7
Sidhu P, O’Kane HO. Self-managed anticoagulation: results from a two-year prospective randomized trial with heart valve patients. Ann Thorac Surg 2001 Nov; 72(5): 1523–7
Wilt VM, Gums JG, Ahmed OI, et al. Outcome analysis of a pharmacist-managed anticoagulation service. Pharmacotherapy 1995; 15(6): 732–9
Cromheecke ME, Levi M, Colly LP, et al. Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomised cross-over comparison. Lancet 2000 Jul; 356(9224): 97–102
Sawicki PT. A structured teaching and self-management program for patients receiving oral anticoagulation: a randomized controlled trial. Working Group for the Study of Patient Self-Management of Oral Anticoagulation. JAMA 1999 Jan; 281(2): 145–50
Eckman MH, Levine HJ, Pauker SG. Decision analytic and cost-effectiveness issues concerning anticoagulant prophylaxis in heart disease. Chest 1992; 102 Suppl. 4: 538S–49S
Menzin J, Boulanger L, Hauch O, et al. The cost of warfarin monitoring in anticoagulation clinics: a multi-site managed care study [abstract]. Value Health 2002; 5(3): 165
Hamby L, Weeks WB, Malikowski C. Complications of warfarin therapy: causes, costs, and the role of the anticoagulation clinic. Eff Clin Pract 2000 Jul–Aug; 3(4): 179–84
Lousberg TR, Witt DM, Beall DG. Evaluation of excessive anticoagulation in a group model health maintenance organization. Arch Intern Med 1998; 158(5): 528–34
Gage BF, Cardinalli AB, Albers GW, et al. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA 1995; 274(23): 1839–45
Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001 May; 285(18): 2370–5
Weitz JI, Crowther M. Direct thrombin inhibitors. Thromb Res 2002 May; 106(3): V275–84
Petersen P, Grind M, Adler J, et al. Ximelagatran versus II: a dose-guiding, tolerability, and safety study. J Am Coll Cardiol 2003 May; 41(9): 1445–51